D-Bifunctional protein deficiency (officially called 17-β-hydroxysteroid dehydrogenase) is an autosomal recessive peroxisomal fatty acid oxidation disorder. Peroxisomal disorders are usually caused by a combination of peroxisomal assembly defects or by deficiencies of specific peroxisomal enzymes. The peroxisome is an organelle in the cell similar to the lysosome that functions to detoxify the cell. Peroxisomes contain many different enzymes, such as catalase, and their main function is to neutralize free radicals and detoxify drugs, such as alcohol. For this reason peroxisomes are ubiquitous in the liver and kidney. D-BP deficiency is the most severe peroxisomal disorder , often resembling Zellweger syndrome . Characteristics of the disorder include neonatal hypotonia and seizures, occurring mostly within the first month of life, as well as visual and hearing impairment . Other symptoms include severe craniofacial disfiguration, psychomotor delay, and neuronal migration defects. Most onsets of the disorder begin in the gestational weeks of development and most affected individuals die within the first two years of life.
DBP deficiency can be divided into three types: type I, characterized by a deficiency in both the hydratase and dehydrogenase units of D-BP; type II, in which only the hydratase unit is non-functional; and type III, with only a deficiency in the dehydrogenase unit . Type I deficient patients showed a large structural modification to the D-BP as a whole. Most of these individuals showed either a deletion or an insertion resulting in a frameshift mutation. Type II and III patients showed small scale changes in the overall structure of D-BP. Amino acid changes in the catalytic domains or those in contact with substrate or cofactors were the main cause of these variations of D-BP deficiency. Other amino acid changes were seen to alter the dimerization of the protein, leading to improper folding. Many mutations have been found in the gene coding for D-BP(HSD17B4)on the q arm two of chromosome five (5q2) in Homo sapiens, most notably individuals homozygous for a missense mutation (616S). 
The DBP protein (79kDa) also known as “multifunctional protein 2”, “multifunctional enzyme 2”, or “D-peroxisomal bifunctional enzyme”, catalyzes the second and third steps of peroxisomal β-oxidation of fatty acids and their derivatives .
thumb|Catalytical activities of the SDR and hydratase domain of the D-bifunctional protein. Moller, G., E.g. Van Grunsven, R.j.a. Wanders, and J. Adamski. "Molecular Basis of D-Bifunctional Protein Deficiency." Molecular and Cellular Endocrinology (2001): 61-70.
A non-functional D-BP protein results in the abnormal accumulation of long chain fatty acids and bile acid intermediates. The D-BP protein contains a peroxisomal targeting signal 1 (PTS1) unit at the C-terminus allowing for its transport into peroxisomes by the PTS1 receptor. Inside the peroxisomes, the D-BP protein is partially cleaved exclusively between the SDR and hydratase domains.
DBP is a stereospecific enzyme; hydratase domain forms only (R)-hydroxy-acyl-CoA intermediates from trans-2-enoyl-CoAs . D-BP is expressed throughout the entire human body, with the highest mRNA levels in the liver and brain. The hydrogenase and hydratase units of DBP exist as dimers, necessary for correct folding and therefore function of the enzyme.
The D-BP gene (HSD17B4), found on the long arm of chromosome 5, consists of 24 exons and 23 introns and is over 100kb in size. Exons 1-12 code for the SDR domain, 12-21 for the hydratase domain, and 21-24 for the SCP2 domain. Transcription is regulated at 400 basepairs upstream of the transcription start site .
Fig. 3: Structural features of the human peroxisomal D-bifunctional protein. The catalytically important cofactor binding site and the active center of the SDR domain as well as the amino acids essential for hydratase activity are indicated above the schematic protein. Positions of the -BP mutations are shown below the scheme of the protein. Arrowheads are grayshaded according to the domain in which the mutation is located. Mutations of different nature are marked: boxed, point mutations; in ovals, in-frame deletions; lined, frameshift mutations causing premature proteins. Moller, G., E.g. Van Grunsven, R.j.a. Wanders, and J. Adamski. "Molecular Basis of D-Bifunctional Protein Deficiency." Molecular and Cellular Endocrinology (2001): 61-70.
The missense mutation G16S is the most common mutation that leads to D-BP deficiency. In a 2006 study in which 110 patients were tested, 28 suffered from this frameshift mutation. The second most frequent mutation was the missense mutation N457Y which was seen in 13 of the 110 patients. Type I patients showed only deletions, insertions, and nonsense mutations were identified, most leading to shortened polypeptides. Most type II patients show missense mutations in D-BP hydratase unit as well as some in-frame deletions. Type III individuals commonly show missense mutations in the coding region of the dehydrogenase domain. 
Enzymatic activity of D-BP fails if the protein cannot effectively bind the cofactor NAD+, as shown in the G16S mutation. Glycine 16 forms a short loop and creates a hole for the adenine ring of NAD+ to enter. Other amino acid side chains alter the shape of this loop due to steric hindrance, and prevent proper NAD+ binding. Other mutations that exist are due to incorrect polypeptide folding. L405 (leucine located at residue 405) located in the substrate binding domain of the hydratase 2 unit, plays an important role in binding CoA ester moiety. One mutation seen in D-BP deficiency patients is caused by a leucine to proline substitution. This breaks the hydrophobic interactions necessary for proper substrate binding with CoA esters.
The most common clinical observations of patients suffering from D-bifunctional protein deficiency include hypotonia, facial and skull dysmorphism, neonatal seizures, and neuronal demyelination  High levels of branched fatty acids, such as pristinic acid, bile acid intermediates, and other D-BP substrates are seen to exist. Reduced pristinic acid β-oxidation is a common indicator of D-BP deficiency . D-BP can be distinguished from Zellweger Syndrome by normal plasmalogen synthesis. Recent studies in D-BP knockout mice show compensatory upregulation of other peroxisomal enzymes in absence of D-BP such as palmitoyl-CoA oxidase, peroxisomal thiolase, and branched chain acyl-CoA oxidase .
 M. Itoh, Y. Suzuki, S. Akaboshi, Z. Zhang, S. Miyabara, S. Takashma. “Developmental and pathological expression of peroxisomal enzymes: their relationship of D-bifunctional protein deficiency and Zellweger syndrome.” Brain Research (200): 40-47. PubMed.
 Elisabeth G. van Grunsven, Petra A. W. Mooijer, Patrick Aubourg, and Ronald J. A. Wanders. “Identification of a new type of D-bifunctional protein deficiency.” Human molecular genetics, Oxford University Press. (1999): 509-1516. PubMed.  Nakano K, Zhang Z, Shimozawa N, Kondo N, Ishii N, Funatsuka M, Shirakawa S, Itoh M, Takashima S, Une M, Kana-aki RR, Mukai K, Osawa M, Suzuki Y. “D-bifunctional protein deficiency with fetal ascites, polyhydramnios, and contractures of hands and toes.” The Journal of pediatrics (2001): 865-867. PubMed.
 G. Möller, E.G. van Grunsven, R.J.A. Wanders, J. Adamski. "Molecular basis of D-bifunctional protein deficiency." Molecular and Cellular Endocrinology (2001) 61-70. PubMed.
 Ferdinandusse, M. Ylianttila, J. Gloerich,. M. Koslo, W. Oostheim, H. Waterham, J. Hultunen, R. Wanders, T. Glumoff. “Mutational Spectrum of D-bifunctional protein Defiency and Structure-Based Genotype-Phenotype Analysis.” The American Journal of Human Genetics (2006):112-124. PubMed.
Researchers Submit Patent Application, "Method of Treating Cancer Using Combination of a Bifunctional Alkylating Agent and DNA Repair Inhibitors", for Approval
Aug 12, 2013; By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- From Washington, D.C., NewsRx journalists report that a...
Researchers Submit Patent Application, "METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING BIFUNCTIONAL SRC 3 shRNA", for Approval
Oct 31, 2013; By a News Reporter-Staff News Editor at Women's Health Weekly -- From Washington, D.C., NewsRx journalists report that a patent...
US Patent Issued to Nissan Chemical Industries on Jan. 4 for "Bifunctional Polymerizable Compound, Polymerizable Liquid Crystal Composition, and Oriented Film" (Japanese Inventor)
Jan 09, 2011; ALEXANDRIA, Va., Jan. 9 -- United States Patent no. 7,862,867, issued on Jan. 4, was assigned to Nissan Chemical Industries Ltd....